

AWARD NUMBER: W81XWH-12-1-0548

TITLE: Anti-CDR3 Therapy for B-Cell Malignancies

PRINCIPAL INVESTIGATOR: Dr. David Fitzgerald

CONTRACTING ORGANIZATION: The Geneva Foundation
Tacoma, WA 98402

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel
Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

☒ Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 30 Sep 2013 - 29 Sep 2014	
"Anti-CDR3 Therapy for B-Cell Malignancies"				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0548	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) David Fitzgerald, PhD email:djpf@helix.nih.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Geneva Foundation 917 Pacific Ave, Suite 600 Tacoma, WA 98402				8. PERFORMING ORGANIZATION REPORT	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research and Materiel Command Ft Detrick, MD 21702				10. SPONSOR/MONITOR'S ACRONYM(S) USAMRAA	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Immunotherapy is rapidly becoming accepted as an effective way to treat human cancer. A large proportion of B-cell malignancies express the product of their re-arranged immunoglobulin (IG) genes on the cell surface. Surface-expressed IG constitutes a de facto tumor-specific target antigen. Here we report that two B-cell tumor cell lines, JVM13 and Mec1, express surface IG. Therefore we cloned and sequenced the cDNA encoding the variable portions of these IGs. Specifically, we identified the CDR3 sequences of the heavy and light chain variable portions for each IG, which constitute the molecular target. We have now engineered the following CDR3 sequences "ARSQGVLTADY"/"QQYYSIPYT" for the Mec1 heavy and light chains respectively and "ASSYYDILTGYLYYFDY"/"SSYTSSSTLMI" for the JVM13 heavy and light chains, into a model antibody 4D5 (see figures 1-5 in the report). The "Tomlinson" human antibody phage library will be used to pan for antibodies that bind these target CDR3s and not the parent 4D5 antibody. To confirm the utility of the Tomlinson library and gain experience with handling this complex selection system we have confirmed selection of phage to a test antigen. Successful expression will lead directly to the selection of CDR3-specific antibody-encoding phage: from which we will make our final immunotherapeutic agents.					
15. SUBJECT TERMS Immunotherapy, B-Cell tumor, cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
				20	

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	10
Reportable Outcomes.....	11
Conclusion.....	12
References.....	13
Appendices.....	15

1. INTRODUCTION:

In the US the incidence of newly diagnosed B-cell leukemias and lymphomas amounts to approximately 100,000 cases per year, leading to 40,000 deaths in the same population. While current treatments are improving, side effects from traditional chemotherapy can be debilitating often causing significant life-long morbidity. Compared with chemotherapy, immunotherapy promises similar or better results with far fewer side effects. A potential treatment for individuals who display immunoglobulin protein on the surface of their malignant cells, is targeted immunotherapy that is cytotoxic for only tumor cells. But such immunotherapy strategies are usually time-consuming and complex to organize. To address this limitation we are attempting to speed and simplify the process of producing antibodies to tumor- expressed surface immunoglobulin. Additionally, once we produce anti-tumor antibodies we plan on 'arming' them with toxins. In this way we will generate novel immunotherapeutic treatments for B-cell malignancies.

2. KEYWORDS:

immunoglobulin, lymphoma, leukemia, immunotherapy phage display, toxin, single chain Fv.

3. OVERALL PROJECT SUMMARY:

Revised Statement of work.

As of July 2014 we completed all parts of Tasks 1'3. Task 3 was completed since the last annual report so details of its successful completion are reported below. This leaves Tasks 4 and 5 in need of completion with a new schedule for completion.

Task 4. Convert single chain Fv from library into a therapeutic antibody

4A.Convert single chain Fv into immunotoxin D end of August 2014

4B. Convert single chain Fv into a full length antibody D end of August 2014

4C. Convert single chain Fv into a Chimeric antigen receptorD end of August 2014.

Notes: converting single chain Fv from selected phage is a simple matter of PCR cloning into existing vectors. Vectors for 'immunotoxin', 'full length antibody' and 'chimeric antigen receptor' are all ready to receive the cloned single Fv sequences. This is why we can aim for the same completion date of Aug31st for each of these subDtasks.

Task 5. Conduct preliminary experiments in tissue culture to characterize the cytotoxic activity of candidate immunotoxins, full length antibodies and chimeric antigen receptor constructs D Sept and Dec 2014. Because our cloning step is several months behind, the tissue culture experiments anticipated in Task 5 are pushed back and now will be performed between Sept and Dec 2014.

Report on the completion of Task 3.

Task 3. Selection of phage that bind to the purified candidate antibody and not to irrelevant antibodies. Phage are from single chain Fv library. Sequence phage that bind to candidate antibodies.

- 3A. Select binders from phage library D month 9.
- 3B. Enrich for high affinity binders via multiple rounds of selection D month 10D11.
- 3C. Sequence phage at the end of three rounds of panning and verify enrichment and sequence as a single chain Fv D month 12D13.

Report:

Previously, we reported on the cloning and sequencing of the rearranged immunoglobulin genes from the MEC-1 and JVM-13 human lymphoma cell lines (Tasks 1 and 2).

Task 3.

The CDR3 sequences from the MEC-1 and JVM-13 Ig genes were grafted into the scaffold single chain Fv antibody, called 4D5 Figs 1 and 2. Both heavy and light chain sequences were grafted into the corresponding locations within the single chain Fv of 4D5, replacing the endogenous CDR3 sequences. We made chimeric scFv constructs with FLAG-tags at the N-terminus and from these plasmids we expressed novel recombinant target proteins. Fig 1 shows a schematic depicting the structure of 4D5 and 4D5 with MEC-1 CDR3 sequences. Fig 2 depicts the structure of 4D5 and 4D5 with JVM13 CDR3 sequences. Thus 4D5-Mec and 4D5-JVM became 'targets' for phage selection using the Tomlinson I antibody library. In summary, we were seeking phage that bound to either 4D5-MEC or 4D5-JVM but did not bind to the parent 4D5 antibody. In this reporting cycle, we are happy to summarize substantial completion of Task 3.

Fig 3 shows a schematic of an M13 phage displaying a single chain Fv. The Tomlinson I phage library contains approximately 1.4×10^8 distinct scFvs of unique specificity, each scFv displayed in the location shown in Fig 3. When we panned this phage library on the 4D5-MEC protein we enriched for 5 phage that bound 4D5-MEC but not the 4D5 parent - see Fig 4. The scFv DNA of each of these phage was then sequenced and found to be unique. The DNA sequences are provided in Figs 5-9 and a multiple alignment is shown in Fig 10. We had trouble refolding the 4D5-JVM protein and noticed that it had a tendency to aggregate. No phage were isolated that exhibited specific binding to 4D5-JVM. Because this represented a technical hurdle and we had good results isolating binders to 4D5-MEC, we advanced the project characterizing the phage that bound to this protein. Fig 11 shows a FACS analysis of phage binding to the surface of Mec-1 cells. This result represents a remarkable achievement. Apparently, the 4D5-Mec recombinant protein looks sufficiently like the surface of the actual MEC-1 cells that binding is retained by all the reactive phage.

As mentioned above, despite extensive panning there were no binders isolated from the Tomlinson I library to 4D5-JVM target protein. We also evaluated the Tomlinson J library extensively and likewise failed to enrich for phage that bound specifically to 4D5-JVM. The reasons for obtaining 5 binding phage to 4D5-MEC and none to 4D5-JVM are currently not understood but are likely related to poor folding of the 4D5-JVM protein. Thus, going forward we are focusing our efforts on the five selected phage, labeled 1, 5, 7, 9 and 10 that bound the 4D5-MEC antibody and also bound the MEC-1 cells. Upon sequencing 2 of the 5 phage we noted stop codons in the framework regions - see Figs 6 and 9. Because phage are grown in tRNA 'TAG-suppressor' strains of E coli, read-through was

allowed and antibody Fv sequences were displayed. However, for expression in mammalian cells or in normal E coli strains, these sequences had to be corrected. Stop codons in suppressor strains are normally read as glutamic acid. This posed a problem going forward. We could replace the stop sequences with a codon encoding glutamic acid and expect to get the same amino acid as inserted by the suppressor strain or we could replace the codon with one that re-introduced the natural framework residue. For Tasks 4 and 5 we have chosen to do both.

4. KEY RESEARCH ACCOMPLISHMENTS:

- We have produced single chain Fv proteins with engrafted sequences taken from the CDR3 sequences of surface immunoglobulins on B-cell tumors (see Fig 1 right hand panel). Producing such single chain Fv proteins, per se, does not constitute the Key Accomplishment. Rather the Key Accomplishment is noted because phage that bind the 4D5-MEC protein **ALSO** bind the surface of MEC-1 cells. Thus, these single chain Fv proteins mimic a structure on the surface of tumor cells. This was the major conceptual goal of the project.

5. CONCLUSION:

It is possible to use cloned sequences from human tumor cells to design mimics of surface immunoglobulin on B-cell tumors. This will improve our ability to produce antibody-based therapeutics.

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

Nothing to report.

7. INVENTIONS, PATENTS AND LICENSES:

Nothing to report.

8. REPORTABLE OUTCOMES:

Phage display was used to select single chain Fvs that bind CDR3 sequences from B-cell tumors. Five phage were isolated, each one capable of binding the surface of the target B-cell.

9. OTHER ACHIEVEMENTS:

Nothing to report.

10. REFERENCES: List all references pertinent to the report using a standard journal format (i.e., format used in *Science*, *Military Medicine*, etc.)

Nothing to report.

11. APPENDICES: Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

Pages shall be consecutively numbered throughout the report. DO NOT RENUMBER PAGES IN THE APPENDICES.

NOTE:

TRAINING OR FELLOWSHIP AWARDS:

Not applicable.

COLLABORATIVE AWARDS:

Not applicable.

QUAD CHARTS:

Not applicable.

DELINQUENT REPORTS

Not applicable.

MANUSCRIPTS/REPRINTS

Not applicable.

ABSTRACTS

Not applicable.

MARKING OF PROPRIETARY INFORMATION:


Not applicable.

Figures:

Fig 1

A.

hum4D5 scFV - WT




H-CDR3 = SRWGGDGFYAMDY 13aa

L-CDR3 = QQHYTTPPT 9 aa

B.

hum4D5 scFV – Mec1_CDR3s



H-CDR3 = ARSQGVLTIDY 12aa

L-CDR3 = QQYYSIPYT 9aa


Legend to Fig 1.

Generation of target proteins by inserting MEC1 CDR3 sequences into the scaffold antibody, 4D5. The idealized structure of the single chain Fv of the 4D5 antibody is shown. The heavy chain (hc) is followed by a flexible peptide linker to join it to the light chain (lc). The yellow sequences, corresponding to CDR1, CDR2 and CDR3, are shown in their approximate location within the heavy and light chains of the 4D5 antibody. Below the antibody structure is listed sequences corresponding to the CDR3 region of heavy and light chains. These sequences are replaced by the CDR3 sequences from the MEC1 surface IgG.

Fig 2

A.


hum4D5 scFV - WT



H-CDR3 = SRWGGDGFYAMDY 13aa
L-CDR3 = QQHYTTPPT 9 aa

B.

hum4D5 scFV – JVM-13_CDR3s




H-CDR3 = ASSYYDILTGYLY 13aa
L-CDR3 = SSYTSSSTLMI 11aa

Legend to Fig 2.

Generation of target proteins by inserting JVM13 CDR3 sequences into the scaffold antibody, 4D5. The idealized structure of the single chain Fv of the 4D5 antibody is shown on the left. The heavy chain (hc) is followed by a flexible peptide linker to join it to the light chain (lc). The yellow sequences, corresponding to CDR1, CDR2 and CDR3, are shown in their approximate location within the heavy and light chains of the 4D5 antibody. Below the antibody structure is listed sequences corresponding to the CDR3 region of heavy and light chains. These sequences are replaced by the CDR3 sequences from the JVM13 surface IgG.

Fig 3.



Legend to Fig 3. Shown is the M13 bacteriophage displaying a single chain Fv fused with one copy of the pIII protein.

Fig 4.

Isolation of Phage binders to 4D5-MEC-1

Tomlinson I scFv Library

 1.4×10^8 clones




Fig 5.

Isolate #1 DNA/and corresponding protein



atggccgaggtgcagctgttgaatctgggggaggcttggtacagcctggggggtccctg
M A E V Q L L E S G G G L V Q P G G S L
agactctcctgtgcagcctctggattcaccttagcagctatgccatgagctgggtccgc
R L S C A A S G F T F S S Y A M S W V R
caggctccaggaaggggctggagtgggtctcatatattacttctaataataataca
Q A P G K G L E W V S Y I T S N G N N T
tcttacgcagactccgtgaagggccggttcacatctccagagacaattccaagaacacg
S Y A D S V K G R F T I S R D N S K N T
ctgtatctgcaaataaacagcctgagagccgaggacacggccgtatattactgtgcgaaa
L Y L Q M N S L R A E D T A V Y Y C A K
actggtggtctttgactactggggccaggaaccctggtcaccgtctcgagcgggtgga
T G G S F D Y W G Q G T L V T V S S G G
ggcgggttcaggcggaggtggcagcggcgggtggcgggtcgacggacatccagatgaccag
G G S G G G G S G G G G S T D I Q M T Q
tctccatcctccctgtctgcatctgtaggagacagagtcacatcacttgccgggcaagt
S P S S L S A S V G D R V T I T C R A S
cagagcattagcagctatttaaattggtatcagcagaaaccagggaagcccctaagctc
Q S I S S Y L N W Y Q Q K P G K A P K L
ctgatctataatgcaccaatttgcaaagtgggtcccatcaagggtcagtggcagtgga
L I Y N A S N L Q S G V P S R F S G S G
tctgggacagatttcactctcaccatcagcagctctgcaacctgaagatttgcaactac
S G T D F T L T I S S L Q P E D F A T Y
tactgtcaacagctctgatagtaatcctgatacgttcggccaagggaccaaggtggaaatc
Y C Q Q S D S N P D T F G Q G T K V E I
aaa
K

MAEVQLLESGLLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYIT
SNGNNT
SYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKTGGSFDYWGQGLVT
VSSGG
GGSGGGGGSGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQKPK
GKAPKL
LIYNASNLSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSDSNPDFTFGQGT

Fig 6. Isolate #5 DNA/and corresponding protein



atggccgaggtgcagctgttgagctctggggaggcttggtatagcctggggggtccctg
M A E V Q L L E S G G G L V - P G G S L
agactctcctgtgcagcctctggattcacctttagcagctatgccatgagctgggtccgc
R L S C A A S G F T F S S Y A M S W V R
caggctccaggggaaggggctggagtggtctcagctattaatagtaatggtgcttataca
Q A P G K G L E W V S A I N S N G A Y T
tcttacgcagactccgtgaagggccggttcaccatctccagagacaattccaagaacacg
S Y A D S V K G R F T I S R D N S K N T
ctgtatctgcaaatgaacagcctgagagccgaggacacggccgtatattactgtgcgaaa
L Y L Q M N S L R A E D T A V Y Y C A K
agttctggttctttgactactggggccagggaaaccctggtcaccgtctcgagcgggtgga
S S G S F D Y W G Q G T L V T V S S G G
ggcgggttcaggcggaggtggcagcggcggtggcggtcgacggacatccagatgacccag
G G S G G G G S G G G G S T D I Q M T Q
tctccatcctccctgtctgcacgtgtgaggagacagagtcaccatcacttgccggggaagt
S P S S L S A S V G D R V T I T C R A S
cagagcattagcagctatttaaattggtatcagcagaaaccagggaaagcccctaagcac
Q S I S S Y L N W Y Q Q K P G K A P K H
ctgatctatgatgcacccggttgcaaagtggggtcccatcaagggtcagtggcagtgga
L I Y D A S G L Q S G V P S R F S G S G
tctgggacagattcactctcaccatcagcagctgcaacctgaagattttgcaactac
S G T D F T L T I S S L Q P E D F A T Y
tactgtcaacagctctggtgctactcctggtacgttcggccaagggaccaaggtggaaatc
Y C Q Q S G A T P G T F G Q G T K V E I
aaa
K

TAG suppressor

MAEVQLLESGGGLV-
PGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSNGAYT
SYADSVKGRFTISRDN SKNTLYLQMNLSLRAEDTAVYYCAKSSGSFDYW GQGLTVTVSSG
G
GGSGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAP
KH
LIYDASGLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSGATPGTFGQGTKVEI
K

Fig 7. Isolate #7 DNA/and corresponding protein



```
atggccgaggtgcagctgttgagctctgggggaggcttggtacagcctggggggtcctg
M A E V Q L L E S G G G L V Q P G G S L
agactctcctgtgcagcctctggattcaccttagcagctatgccatgagctgggtccgc
R L S C A A S G F T F S S Y A M S W V R
caggctccaggaaggggctggagtggtctcaaattactgatagtgggtatactaca
Q A P G K G L E W V S N I T D S G Y T T
tcttacgcagactccgtgaagggcaggttcaccatctccagagacaattccaagaacacg
S Y A D S V K G R F T I S R D N S K N T
ctgtatctgcaaatgaacagcctgagagccgaggacacggccgtatattactgtgcgaaa
L Y L Q M N S L R A E D T A V Y Y C A K
actggaatagttttgactactggggccaggaaccctggtgaccgtctcgagcggtgga
T G N S F D Y W G Q G T L V T V S S G G
ggcgggttcaggcggaggtggcagcggcgggtggcgggtcgacggacatccagatgaccag
G G S G G G G S G G G G S T D I Q M T Q
tctccatcctcctgtctgcacgtgtaggagacagagtcaccatcacttgccgggcaagt
S P S S L S A S V G D R V T I T C R A S
cagagcattagcagctatttaaattggtatcagcagaaaccagggaaagcccctaagcac
Q S I S S Y L N W Y Q Q K P G K A P K H
ctgatctatgctgcacacctattgcaaagtgggggtcccatcaagggtcagtggcagtgga
L I Y A A S Y L Q S G V P S R F S G S G
tctgggacagatttcactctcaccatcagcagctctgcaacctgaagattttgcaacttac
S G T D F T L T I S S L Q P E D F A T Y
tactgtcaacatgatactactactcctagtagtgcggccaagggaccaaggtggaaatc
Y C Q H D T T T P S T F G Q G T K V E I
```

aaa

K

```
MAEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSNITDSGY
TT
SYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKTGNSFDYWGQGLTVTVSSG
G
GGSGGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAP
KH
LIYAASYLQSGVPSRFSGSG
L I Y A A S Y L Q S G V P S R F S G S G
L I Y A A S Y L Q S G V P S R F S G S G
```


Fig 8.

Isolate #9 DNA/and corresponding protein



atggccgaggtgcagctgttgagctctgggggaggcttggtacagcctggggggtcctg
M A E V Q L L E S G G G L V Q P G G S L
agactctcctgtgcagcctctggattcaccttagcagctatgccatgagctgggtccgc
R L S C A A S G F T F S S Y A M S W V R
caggctccaggaaggggctggagtgggtctcaaataattactttagtggtactggtaca
Q A P G K G L E W V S N I T S S G T G T
tattacgcagactccgtgaagggcaggtcaccatctccagagacaattccaagaacacg
Y Y A D S V K G R F T I S R D N S K N T
ctgtatctgcaaatgaacagcctgagagccgaggacacggccgtatattactgtgcgaaa
L Y L Q M N S L R A E D T A V Y Y C A K
gcttcttctgctttgactactggggccaggaaccctgggtcaccgtctcgagcgggtgga
A S S A F D Y W G Q G T L V T V S S G G
ggcgggtcaggcggaggtggcagcggcgggtggcgggtcgacggacatccagatgaccag
G G S G G G G S G G G G S T D I Q M T Q
tctccatcctcctgtctgcatctgtaggagacagagtcaccatcactgcccgggcaagt
S P S S L S A S V G D R V T I T C R A S
cagagcattagcagctatttaaattggtatcagcagaaaccagggaagcccctaagctc
Q S I S S Y L N W Y Q Q K P G K A P K L
ctgatctataatgcatccgatttgcaaagtgggtcccatcaagggtcagtggcagtgga
L I Y N A S D L Q S G V P S R F S G S G
tctgggacagatttactctcaccatcagcagtcgtgcaacctgaagattttgcaacttac
S G T D F T L T I S S L Q P E D F A T Y
tactgtcaacaggataatagtactcctgatacgttcggccaagggaccaaggtggaaatc
Y C Q Q D N S T P D T F G Q G T K V E I
aaa
K

MAEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSNITSSGTGT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKASSAFDYWGQGLVTVSSGG
GGSGGGGGSGGGGGSTDIQMTQSPSSLSASVGD RVTITCRASQSISSYLNWYQQKPGKAPKL
LIYNASDLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQDNSTPDTFGQGTKVEI
K

Fig 9 Isolate #10 DNA/and corresponding protein



TAG suppressor

atggccgaggtgcagctgttgagctctgggggaggcttggtacagcctggggggtccctg
M A E V Q L L E S G G G L V Q P G G S L
agactctctgtgcagcctctggattcaccttagcagctatgccatgagctgggtccgc
R L S C A A S G F T F S S Y A M S W V R
caggctccaggggaaggggctggagtaggtctcatatattgctgctgagggtagtactaca
Q A P G K G L E - V S Y I A A E G S T T
tattacgcagactccgtgaagggccggtcaccatctccagagacaattccaagaacacg
Y Y A D S V K G R F T I S R D N S K N T
ctgtatctgcaaatgaacagcctgagagccgaggacacggccgtatattactgtgcgaaa
L Y L Q M N S L R A E D T A V Y Y C A K
tctactggtacttttgactactggggccagggaaaccctggtcaccgtctcgagcgggtgga
S T G T F D Y W G Q G T L V T V S S G G
ggcgggtcaggcggaggtggcagcggcgggtggcgggtcgacggacatccagatgaccag
G G S G G G G S G G G G S T D I Q M T Q
tctccatctccctgtctgcatctgtaggagacagagtcaccatcacttgccgggcaagt
S P S S L S A S V G D R V T I T C R A S
cagagcattagcagctatttaaattggtatcagcagaaaccagggaaagcccctaagctc
Q S I S S Y L N W Y Q Q K P G K A P K L
ctgatctataatgcatccgctttgcaaagtggggtcccatcaagggtcagtggcagtgga
L I Y N A S A L Q S G V P S R F S G S G
tctgggacagatttcactctcaccatcagcagctctgcaacctgaagattttgcaacttac
S G T D F T L T I S S L Q P E D F A T Y
tactgtcaacaggatgattctgctcctgatacgttcggccaagggaaggtggaaatc
Y C Q Q D D S A P D T F G Q G T K V E I
aaa
K

MAEVQLLES GGGLVQPGGSLRLS CAASGFTFSSYAMSWVRQAPGKGLE-VSYIAAEGSTT
YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKSTGTFDYW GQGTLTVSSGG
GGSGGGGGSGGGGGSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL
LIYNASALQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDD SAPDTFGQGTKVEI
K

Fig 10 Alignments confirms that the antibody Fvs from each phage represents a unique sequence

```
Isolate1  1 MAEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVS YITSNGNNT 60
Isolate5  1 MAEVQLLES GGGLVXPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSNGAYT 60
Isolate7  1 MAEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSNITDSGYTT 60
Isolate9  1 MAEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSNITSSGTGT 60
Isolate10 1 MAEVQLLES GGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEXVSYIAAEGSTT 60
*****
```

```
Isolate1  61 SYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKTGGSF DYWGQGTLVTVSSGG 120
Isolate5  61 SYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKSSGSF DYWGQGTLVTVSSGG 120
Isolate7  61 SYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKTGNSF DYWGQGTLVTVSSGG 120
Isolate9  61 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKASSAF DYWGQGTLVTVSSGG 120
Isolate10 61 YYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKSTGT FDYWGQGTLVTVSSGG 120
*****
```

```
Isolate1  121 GGS GGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL 180
Isolate5  121 GGS GGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKH 180
Isolate7  121 GGS GGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKH 180
Isolate9  121 GGS GGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL 180
Isolate10 121 GGS GGGGSGGGGSTD IQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKL 180
*****
```

```
Isolate1  181 LIYNASNLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQSDSNPDTFGQG TKVEI 240
Isolate5  181 LIYDASGLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQSGATPGTFGQG TKVEI 240
Isolate7  181 LIYAASYLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQHDTTTPSTFGQG TKVEI 240
Isolate9  181 LIYNASDLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQDNSTPDTFGQG TKVEI 240
Isolate10 181 LIYNASALQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQDDSAPDTFGQG TKVEI 240
*** ** *****
```

Isolate1 241 K 241
Isolate5 241 K 241
Isolate7 241 K 241
Isolate9 241 K 241
Isolate10 241 K 241


Legend to Fig 11. X equals location of stop codon. Stop codons were engineered/mutated to encode either the normal framework residue Q and W respectively or replaced with 'E' – the amino acid inserted by the suppressor strain.

Fig 11.


Phage binding to the surface of MEC-1 Cells

Phage #


(-)



(10)




(9)




Phage #


(7)



(5)



(1)



Legend to Fig 12. Data shows binding in area 'P4' of phage to intact Mec-1 cells.